Sagimet Biosciences Inc. (SGMT)
NASDAQ: SGMT · Real-Time Price · USD
6.56
+0.33 (5.30%)
At close: Feb 3, 2026, 4:00 PM EST
6.51
-0.05 (-0.76%)
Pre-market: Feb 4, 2026, 7:51 AM EST
Sagimet Biosciences Employees
Sagimet Biosciences had 14 employees as of December 31, 2024. The number of employees increased by 4 or 40.00% compared to the previous year.
Employees
14
Change (1Y)
4
Growth (1Y)
40.00%
Revenue / Employee
n/a
Profits / Employee
-$4,119,357
Market Cap
213.34M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2024 | 14 | 4 | 40.00% | 14 | 0 |
| Dec 31, 2023 | 10 | 0 | - | 8 | 2 |
| Dec 31, 2022 | 10 | 3 | 42.86% | 9 | 1 |
| Dec 31, 2020 | 7 | - | - | 6 | 1 |
Related Stocks
Employee RankingsSGMT News
- 2 days ago - Sagimet Announces Positive 52-Week Data from License Partner Ascletis' Open-Label Phase 3 Clinical Trial Evaluating the Long-Term Safety of ASC40 (Denifanstat) Tablets in Patients with Moderate to Severe Acne - GlobeNewsWire
- 6 days ago - Ascletis Announces Positive Topline Results from Its Phase III Open-Label Study of Denifanstat (ASC40), a First-in-Class, Once-Daily Oral FASN Inhibitor for Acne - PRNewsWire
- 8 days ago - Biotech Veteran and Virologist Joins CancerVax as Senior Scientific Advisor - GlobeNewsWire
- 27 days ago - Sagimet Biosciences Announces Poster Presentation at the 10th Annual MASH-TAG 2026 Conference - GlobeNewsWire
- 6 weeks ago - Sagimet: Positive Denifanstat Combination PK Data Could Lead To Untapped Market - Seeking Alpha
- 6 weeks ago - Sagimet Biosciences Announces Positive Results from the Phase 1 PK Clinical Trial of Denifanstat and Resmetirom Combination - GlobeNewsWire
- 2 months ago - Sagimet's License Partner Ascletis Announced Acceptance of New Drug Application for Denifanstat for the Treatment of Moderate to Severe Acne by China's National Medical Products Administration - GlobeNewsWire
- 2 months ago - Ascletis Announces China National Medical Products Administration Acceptance of New Drug Application for Denifanstat (ASC40), a First-in-Class FASN Inhibitor for Acne Treatment - PRNewsWire